1 Min Read
April 3 (Reuters) - Oncomed Pharmaceuticals Inc:
* Plans to initiate a phase 1a single-agent study of its anti-TIGIT antibody (OMP-313M32) in first half of 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.